Top searches

PL

Resources

B2RLaw advises biotech company Ambulero on fundraising

27/01/2021

B2RLaw has advised Ambulero, Inc., a biotechnology company developing cell and gene therapy treatments for patients suffering from vascular disease on funding of up to USD 5.5 million received from from Orphinic Scientific.

As part of the investment, and with the help of B2RLaw, Ambulero and Orphinic formed a Polish subsidiary (Ambulero Sp. z o.o.) that will lead clinical testing of a novel gene therapy for a serious vascular disease in Europe. The disease is rare in the US but more common in certain parts of Central and Eastern Europe.

Ambulero is a biotechnology company dedicated to advancing a platform of cell and gene therapies to treat serious vascular diseases. The company is a 2019 spin-out of the University of Miami co-founded by Robert L. Buchanan, Randy Berholtz, Omaida C. Velazquez and Jun Zhao-Liu. It holds an exclusive license from the University of Miami to develop and commercialize research from the laboratories of Drs. Omaida C. Velazquez and Jun Zhao-Liu.

With offices in Palo Alto, California and Warsaw, Poland, Orphinic Scientific is an innovative drug development and investment company focused on mid-market opportunities and orphan drugs in late preclinical research and Phase 1 or 2.

B2RLaw’s team was led by Partner Szymon Syp and included Senior Associate Iga Wojtczak – Opala and Junior Associate Jakub Niemiec.

Szymon Syp advises, “We congratulate Ambulero and Orphinic Scientific on this transaction. Ambulero’s important work means that people that suffer from serious vascular disease (which at best, causes severe discomfort and at worst, can result in death) can live in comfort with the knowledge that innovative treatment is on the horizon. We wish Ambulero the best of luck on its future clinical testing”.

View more resources

Catch up on the very latest B2RLAW
announcements and news here.

13/11/2023

Danyila Zubach on WEB3: Impact The Economy Summit

WEB3: Impact the Economy was a discussion about the realities and opportunities of WEB3economy. It gathered policymakers, founders, CEOs of […]

MORE
24/10/2023

B2RLaw in the Bay Area and Silicon Valley on 24th October – 1st November

Here we go again on our US roadshow! Meet us in the Bay and Area Silicon Valley on 24th October […]

MORE
16/10/2023

B2RLaw advised Everfield UK Limited in the acquisition of 100% of the shares of a Polish start-up – Grafik Optymalny

Everfield is an international IT group that invests in companies with specialized software that solves operational problems for businesses. They […]

MORE
10/10/2023

B2RLaw advises Vestas on the acquisition of the ST3 Offshore for over PLN 170 million

B2RLaw advises Vestas on the acquisition of the ST3 Offshore for over PLN 170 million. Vestas, the Danish global giant […]

MORE
09/10/2023

B2RLaw’s team advised IQ Biozoom in connection with the investment support received from VC Link

B2RLaw’s team advised IQ Biozoom in connection with the investment support received from VC Link. IQ Biozoom is a Polish […]

MORE
22/09/2023

Julia Stroińska at the Modern Lawyer’s Conference “Law and Technology in the 21st Century”

Today at the Modern Lawyer’s Conference ”Law and Technology in the 21st Century“, organised by the Center for American Studies Poland, Julia Stroińska, Junior […]

MORE

Get in touch

Not sure who to contact? Let us help you find the right lawyer.

This site uses cookies to improve your experience More information.

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.

Close